Transition Therapeutics Inc.
101 College Street
Suite 220
Toronto,
ON M5G 1L7
Canada - Map
Phone: 416-260-7770
Fax: 416-260-2886
Web Site: http://www.transitiontherapeutics.com
| Transition Therapeutics Inc., a biopharmaceutical company, develops novel therapeutics for various disease indications primarily in Canada. Its lead products include ELND-005/AZD-103, a Phase II clinical trial product for the treatment of Alzheimer's disease; and TT-223 gastrin analogue, a Phase II clinical trial product for the treatment of diabetes. The companys TT-223 gastrin analogue, includes TT-223 in combination with a GLP-1 analogue as a therapy for the treatment of type 1 and type 2 diabetes, which is under Phase 1b clinical study in type 2 diabetes patients; and TT-223 in combination with EGF analogues that has completed two Phase I clinical trials for the drug candidate in type 1 and type 2 diabetics. In addition, it has an emerging pipeline of preclinical drug candidates developed using its proprietary drug discovery engine. Transition Therapeutics Inc. has a strategic collaboration with Elan Pharma International Limited to develop and commercialize ELND-005/AZD-103 therapeutic agent, as well as a licensing and collaboration agreement with Eli Lilly and Company to develop and commercialize gastrin based therapies, including the lead compound TT-223. The company was formerly known as Transition Therapeutics and Diagnostics Inc. and changed its name to Transition Therapeutics Inc. in December 2000. Transition Therapeutics Inc. was founded in 1987 and is based in Toronto, Canada. |
|
| Key Statistics |
| |
| | Pay | Exercised | Dr. Tony F. Cruz Ph.D.,
Chairman and Chief Exec. Officer |
N/A
| N/A | Mr. Elie Farah C.F.A., C.A., MAcc,
Pres and Chief Financial Officer |
N/A
| N/A | Mr. Carl Damiani ,
VP of Bus. Devel. |
N/A
| N/A | Dr. Aleksandra Pastrak ,
VP of Research and Medical Officer |
N/A
| N/A | Ms. Nicole Rusaw-George ,
VP of Fin. |
$
174.00K | N/A |
|
|
|
Dollar amounts are as of
31-Dec-09
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
0.02% Nasdaq 
0.38%
Profile
